Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

被引：0
|
作者：
Jason D. Lickliter
Mark Voskoboynik
Linda Mileshkin
Hui K. Gan
Ganessan Kichenadasse
Kathy Zhang
Maggie Zhang
Zhiyu Tang
Michael Millward
机构：
[1] Nucleus Network,Department of Medicine
[2] Central Clinical School,undefined
[3] Monash University,undefined
[4] Peter MacCallum Cancer Centre-East Melbourne,undefined
[5] Olivia Newton-John Cancer Wellness and Research Centre,undefined
[6] Austin Hospital,undefined
[7] Heidelberg,undefined
[8] La Trobe University School of Cancer Medicine,undefined
[9] University of Melbourne,undefined
[10] Flinders Centre for Innovation in Cancer,undefined
[11] Flinders Medical Centre,undefined
[12] BeiGene USA,undefined
[13] Inc.,undefined
[14] Linear Clinical Research & University of Western Australia,undefined
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 585
页数：9
相关论文
共 50 条
  • [31] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [32] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
    Amita Patnaik
    Glen J. Weiss
    Drew W. Rasco
    Lisa Blaydorn
    Amy Mirabella
    Murali Beeram
    Wei Guo
    Sharon Lu
    Hadi Danaee
    Kristen McEachern
    Ellie Im
    Jasgit C. Sachdev
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 93 - 103
  • [33] A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
    Ramasamy, Karthik
    Nooka, Ajay
    Quach, Hang
    Htut, Myo
    Popat, Rakesh
    Liedtke, Michaela
    Tuchman, Sascha A.
    Laubach, Jacob
    Gasparetto, Cristina
    Chanan-Khan, Asher
    Hertzberg, Mark
    deMario, Mark
    Nueesch, Eveline
    Chesne, Evelyne
    Franjkovic, Izolda
    Lechner, Katharina
    Kornacker, Martin
    Cho, Hearn Jay
    BLOOD CANCER JOURNAL, 2021, 11 (09)
  • [34] A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
    Karthik Ramasamy
    Ajay Nooka
    Hang Quach
    Myo Htut
    Rakesh Popat
    Michaela Liedtke
    Sascha A. Tuchman
    Jacob Laubach
    Cristina Gasparetto
    Asher Chanan-Khan
    Mark Hertzberg
    Mark deMario
    Eveline Nueesch
    Evelyne Chesne
    Izolda Franjkovic
    Katharina Lechner
    Martin Kornacker
    Hearn Jay Cho
    Blood Cancer Journal, 11
  • [35] Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
    Heery, Christopher R.
    O'Sullivan-Coyne, Geraldine
    Madan, Ravi A.
    Cordes, Lisa
    Rajan, Arun
    Rauckhorst, Myrna
    Lamping, Elizabeth
    Oyelakin, Israel
    Marte, Jennifer L.
    Lepone, Lauren M.
    Donahue, Renee N.
    Grenga, Italia
    Cuillerot, Jean-Marie
    Neuteboom, Berend
    von Heydebreck, Anja
    Chin, Kevin
    Schlom, Jeffrey
    Gulley, James L.
    LANCET ONCOLOGY, 2017, 18 (05): : 587 - 598
  • [36] The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
    Yonemori, Kan
    Shimizu, Toshio
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Kitano, Shigehisa
    Sato, Jun
    Shimomura, Akihiko
    Shibaki, Ryota
    Suri, Ajit
    Kase, Yoichi
    Sumino, Shuuji
    Tamura, Kenji
    Yamamoto, Noboru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 693 - 699
  • [37] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [38] A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.
    Puzanov, Igor
    LoRusso, Patricia
    Papadopoulos, Kyriakos P.
    Chen, Christopher T.
    LeBruchec, Yvan
    He, Xiaomin
    Cousin, Thierry
    Havenith, Karin
    Boni, Joseph
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] A PHASE 1/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Luke, Jason
    Janku, Filip
    Olszanski, Anthony
    Leach, Kevin
    Iyer, Radhakrishnan
    Abbas, Atif
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A224 - A224
  • [40] Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study
    Ito, Yoshinori
    Suenaga, Mitsukuni
    Hatake, Kiyohiko
    Takahashi, Shunji
    Yokoyama, Masahiro
    Onozawa, Yusuke
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Hashigami, Kiyoshi
    Hasegawa, Hirotaka
    Takenaka, Nobuko
    Boku, Narikazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (04) : 278 - 286
12345